Efficacy of various dosing frequencies of dupilumab in patients with aspirin-exacerbated respiratory disease.
作者信息
Brown Alyson N, Laidlaw Tanya M, Buchheit Kathleen M, Bensko Jillian C, Corcoran Rose C, Bailey Laura B
机构信息
Division of Allergy and Clinical Immunology, Jeff and Penny Vinik Center, Brigham and Women's Hospital, Boston, Mass.
Division of Allergy and Clinical Immunology, Jeff and Penny Vinik Center, Brigham and Women's Hospital, Boston, Mass; Department of Medicine, Harvard Medical School, Boston, Mass.
出版信息
J Allergy Clin Immunol Pract. 2024 Jun;12(6):1647-1648. doi: 10.1016/j.jaip.2024.03.011. Epub 2024 Mar 12.
Abstract
摘要
相似文献
1
Efficacy of various dosing frequencies of dupilumab in patients with aspirin-exacerbated respiratory disease.度普利尤单抗不同给药频率对阿司匹林加重的呼吸系统疾病患者的疗效
J Allergy Clin Immunol Pract. 2024 Jun;12(6):1647-1648. doi: 10.1016/j.jaip.2024.03.011. Epub 2024 Mar 12.
2
Dupilumab increases aspirin tolerance in aspirin-exacerbated respiratory disease.度普利尤单抗可提高阿司匹林诱发的呼吸道疾病患者对阿司匹林的耐受性。
Ann Allergy Asthma Immunol. 2021 Jun;126(6):738-739. doi: 10.1016/j.anai.2021.03.010. Epub 2021 Mar 19.
3
Co-treatment of non-steroidal anti-inflammatory drug-exacerbated respiratory disease with dupilumab and aspirin therapy after desensitization.脱敏后使用度普利尤单抗和阿司匹林治疗非甾体抗炎药加重的呼吸道疾病的联合治疗。
Clin Exp Allergy. 2023 Sep;53(9):974-977. doi: 10.1111/cea.14348. Epub 2023 May 29.
4
Dupilumab-associated arthralgia in patients with aspirin-exacerbated respiratory disease.阿司匹林加重性呼吸系统疾病患者中与度普利尤单抗相关的关节痛
Ann Allergy Asthma Immunol. 2022 Apr;128(4):469-472. doi: 10.1016/j.anai.2022.01.036. Epub 2022 Feb 3.
5
Poor control of asthma symptoms with interleukin-5 inhibitors in four patients with aspirin-exacerbated respiratory disease.在四名阿司匹林诱发的呼吸道疾病患者中，白细胞介素-5抑制剂对哮喘症状的控制不佳。
Ann Allergy Asthma Immunol. 2020 Jan;124(1):102-104. doi: 10.1016/j.anai.2019.09.023. Epub 2019 Oct 9.
6
Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease.度普利尤单抗作为阿司匹林加重性呼吸道疾病患者手术的辅助治疗药物。
Ann Allergy Asthma Immunol. 2022 Mar;128(3):326-328. doi: 10.1016/j.anai.2021.11.020. Epub 2021 Dec 1.
7
Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin-exacerbated urticaria and respiratory disease.在一名患有阿司匹林诱发的荨麻疹和呼吸道疾病的患者中，奥马珠单抗治疗后实现了阿司匹林脱敏。
J Investig Allergol Clin Immunol. 2015;25(2):133-5.
8
Dupilumab Treatment for Aspirin-Exacerbated Respiratory Disease in a Real-World Setting: Impact on Quality of Life and Healthcare Utilization.度普利尤单抗在真实世界中治疗阿司匹林诱发的呼吸道疾病：对生活质量和医疗保健利用的影响。
Am J Rhinol Allergy. 2025 Mar;39(2):90-97. doi: 10.1177/19458924241298817. Epub 2024 Nov 22.
9
Mepolizumab for the treatment of aspirin-exacerbated respiratory disease associated with coronary spasm.美泊利单抗用于治疗与冠状动脉痉挛相关的阿司匹林加重性呼吸疾病。
J Allergy Clin Immunol Pract. 2019 Mar;7(3):1076-1077. doi: 10.1016/j.jaip.2018.07.045. Epub 2018 Aug 29.
10
Dupilumab improves alcohol tolerance in aspirin-exacerbated respiratory disease.度普利尤单抗可改善阿司匹林诱发的呼吸道疾病中的酒精耐受性。
Ann Allergy Asthma Immunol. 2021 Sep;127(3):379-381. doi: 10.1016/j.anai.2021.05.005. Epub 2021 May 15.
引用本文的文献
1
Two-Year Data of Tapered Dupilumab Shows High Effectiveness in Chronic Rhinosinusitis with Nasal Polyps With Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease.度普利尤单抗减量治疗两年的数据显示，其对伴有非甾体抗炎药加重的呼吸系统疾病的慢性鼻-鼻窦炎伴鼻息肉具有高效性。
Allergy. 2025 Jun;80(6):1737-1745. doi: 10.1111/all.16579. Epub 2025 May 16.
2
Clinical efficacy and mechanisms of biologics for chronic rhinosinusitis with nasal polyps.生物制剂治疗伴有鼻息肉的慢性鼻-鼻窦炎的临床疗效及机制
J Allergy Clin Immunol. 2025 May;155(5):1401-1410. doi: 10.1016/j.jaci.2025.03.011. Epub 2025 Mar 23.
本文引用的文献
1
Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease.度普利尤单抗在阿司匹林加重性呼吸道疾病中的快速和持续疗效及其作用机制。
J Allergy Clin Immunol. 2022 Aug;150(2):415-424. doi: 10.1016/j.jaci.2022.04.007. Epub 2022 Apr 20.
2
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.度普利尤单抗治疗伴有鼻息肉的重度慢性鼻-鼻窦炎患者的疗效和安全性（LIBERTY NP SINUS-24 和 LIBERTY NP SINUS-52）：两项多中心、随机、双盲、安慰剂对照、平行分组 3 期临床试验的结果。
Lancet. 2019 Nov 2;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1. Epub 2019 Sep 19.
3
Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD.度普利尤单抗可改善慢性鼻-鼻窦炎伴鼻息肉和阿司匹林性呼吸道疾病患者的鼻息肉负担并控制哮喘。
J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2462-2465.e1. doi: 10.1016/j.jaip.2019.03.044. Epub 2019 Apr 4.
4
Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis.阿司匹林加重性呼吸疾病作为慢性鼻-鼻窦炎的一种内型
Immunol Allergy Clin North Am. 2016 Nov;36(4):669-680. doi: 10.1016/j.iac.2016.06.004. Epub 2016 Sep 13.
5
Update on the Management of Aspirin-Exacerbated Respiratory Disease.阿司匹林诱发的呼吸道疾病管理的最新进展
Allergy Asthma Immunol Res. 2016 Jul;8(4):298-304. doi: 10.4168/aair.2016.8.4.298.
Zotero 插件